Citigroup Maintains Neutral on Regeneron Pharmaceuticals, Raises Price Target to $740

Benzinga · 1d ago
Citigroup analyst Geoff Meacham maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Neutral and raises the price target from $700 to $740.